Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Cara Therapeutics (CARA) Stock Price
Media coverage about Cara Therapeutics (NASDAQ:CARA) has been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cara Therapeutics earned a news impact score of 0.12 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.6934178619119 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Chelsea bid for Rafinha rejected by Bayern Munich (topactu.net)
- Chelsea showing interest in Bayern Munich right-back, Rafinha (fishinghd.com)
- Asset Advisors Corp Sells 2575 Shares of Procter & Gamble Company (The) (PG) (fishinghd.com)
- Chart Trading: Viewing Signals For Cara Therapeutics Inc (CARA … – Danville Daily (danvilledaily.com)
- Cara Therapeutics Inc (CARA) and PowerShares DB Agriculture Fund (DBA) Shares Moving The Tape in Session – FLBC News (flbcnews.com)
Cara Therapeutics (NASDAQ CARA) traded up 11.43% on Thursday, reaching $14.33. The company had a trading volume of 1,728,375 shares. The firm’s market capitalization is $466.89 million. The stock’s 50-day moving average price is $14.06 and its 200 day moving average price is $16.29. Cara Therapeutics has a 52-week low of $5.27 and a 52-week high of $28.50.
Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.32. During the same period last year, the company earned ($0.48) earnings per share. The business’s quarterly revenue was down 100.0% on a year-over-year basis. On average, equities analysts anticipate that Cara Therapeutics will post ($1.78) earnings per share for the current fiscal year.
A number of equities research analysts have recently weighed in on the company. Canaccord Genuity set a $25.00 price objective on Cara Therapeutics and gave the company a “buy” rating in a research note on Saturday, July 1st. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Cara Therapeutics in a research note on Saturday, July 1st. Vetr cut Cara Therapeutics from a “strong-buy” rating to a “buy” rating and set a $21.73 price objective for the company. in a research note on Wednesday, June 21st. Royal Bank Of Canada dropped their price objective on Cara Therapeutics from $32.00 to $31.00 and set an “outperform” rating for the company in a research note on Monday, May 15th. Finally, Janney Montgomery Scott cut Cara Therapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $22.00 to $21.00 in a research note on Friday, June 30th. Four investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $25.50.
WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Cara Therapeutics (CARA) Stock Price” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/31/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-cara-therapeutics-cara-stock-price.html.
In other news, CEO Derek T. Chalmers sold 25,000 shares of the firm’s stock in a transaction dated Friday, July 14th. The stock was sold at an average price of $15.05, for a total transaction of $376,250.00. Following the completion of the sale, the chief executive officer now directly owns 1,107,292 shares in the company, valued at $16,664,744.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Dean Slagel sold 250,000 shares of the firm’s stock in a transaction dated Thursday, June 29th. The shares were sold at an average price of $25.87, for a total value of $6,467,500.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 278,000 shares of company stock valued at $6,888,750. 7.70% of the stock is owned by insiders.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.
Receive News & Stock Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related stocks with our FREE daily email newsletter.